TGF-β inhibitors for the treatment of cancer

被引：64
|
作者：
Lahn, M [1 ]
Kloeker, S [1 ]
Berry, BS [1 ]
机构：
[1] Eli Lilly & Co, Lilly Corp Ctr, Lilly Res Labs, Therapeut Area Oncol, Indianapolis, IN 46285 USA
来源：
EXPERT OPINION ON INVESTIGATIONAL DRUGS | 2005年 / 14卷 / 06期
关键词：
antisense oligonucleotide; cancer; clinical Studies; knockout mice; monoclonal antibodies; TGF-beta; TGF-beta RI kinase inhibitors;
D O I：
10.1517/13543784.14.6.629
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Advances in understanding the role of transforming growth factor (TGF)-beta in tumorigenesis have led to the development of TGF-beta inhibitors for cancer treatment. Three platforms of TGF-beta inhibitors have evolved: antisense oligonucleotides, monoclonal antibodies and small molecules. in this review, the current stage of development of each known TGF-beta inhibitor will be discussed. As part of the risk/benefit assessment of TGF-beta inhibitors, the known effects of TGF-beta deficiency in mice, non-clinical toxicology studies with TGF-beta inhibitors in rats, and the clinical studies with monoclonal antibodies against TGF-beta will be summarised.
引用
收藏
页码：629 / 641
页数：13
相关论文
共 50 条
  • [1] A Perspective on the Development of TGF-β Inhibitors for Cancer Treatment
    Huynh, Linh Khanh
    Hipolito, Christopher John
    ten Dijke, Peter
    BIOMOLECULES, 2019, 9 (11)
  • [2] Recent progress in TGF-β inhibitors for cancer therapy
    Huang, Cheng-Yi
    Chung, Chih-Ling
    Hu, Tsung-Hui
    Chen, Jih-Jung
    Liu, Pei-Feng
    Chen, Chun-Lin
    BIOMEDICINE & PHARMACOTHERAPY, 2021, 134
  • [3] Development of TGF-β signalling inhibitors for cancer therapy
    Yingling, JM
    Blanchard, KL
    Sawyer, JS
    NATURE REVIEWS DRUG DISCOVERY, 2004, 3 (12) : 1011 - 1022
  • [4] Development of TGF-β signalling inhibitors for cancer therapy
    Jonathan M. Yingling
    Kerry L. Blanchard
    J. Scott Sawyer
    Nature Reviews Drug Discovery, 2004, 3 : 1011 - 1022
  • [5] TGF-β and cancer
    Bierie, B
    Moses, HL
    CYTOKINE & GROWTH FACTOR REVIEWS, 2006, 17 (1-2) : 29 - 40
  • [6] TGF-β and cancer
    Reiss, M
    MICROBES AND INFECTION, 1999, 1 (15) : 1327 - 1347
  • [7] Mesothelin and TGF-α predict pancreatic cancer cell sensitivity to EGFR inhibitors and effective combination treatment with trametinib
    Poteet, Ethan
    Liu, Dongliang
    Liang, Zhengdong
    Van Buren, George
    Chen, Changyi
    Yao, Qizhi
    PLOS ONE, 2019, 14 (03):
  • [8] TGF-β in cancer and bone: Implications for treatment of bone metastases
    Juarez, Patricia
    Guise, Theresa A.
    BONE, 2011, 48 (01) : 23 - 29
  • [9] TGF-β, EMT, and resistance to anti-cancer treatment
    Wang, Xuecong
    Eichhorn, Pieter Johan Adam
    Thiery, Jean Paul
    SEMINARS IN CANCER BIOLOGY, 2023, 97 : 1 - 11
  • [10] TGF-β and Cancer Immunotherapy
    MaruYama, Takashi
    Chen, WanJun
    Shibata, Hiroyuki
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2022, 45 (02) : 155 - 161
12345